BPC-157 vs Tesa/IPA Protocol
Extensively Studied vs Limited Research
compatible Different mechanisms; can complement for healing with GH support.
Molecular Data
BPC-157 Tesa/IPA Protocol
Weight 1,419.53 Da —
Half-life <30 minutes —
Chain 15 amino acids —
Type Pentadecapeptide Dual GH secretagogue combination
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Tesa/IPA Protocol
01 Synergistic GH release from dual pathways
02 More physiological pulsatile GH secretion
03 Tesamorelin's proven lipodystrophy benefits
04 Ipamorelin's clean side effect profile
05 Does not significantly affect cortisol or prolactin
06 Single injection convenience
07 May improve body composition, sleep, and recovery
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Tesa/IPA Protocol
200-500mcg total blend per injection / Once daily (evening preferred) or twice daily for advanced protocols
Standard protocol (5/5 blend) 200-400mcg total Once daily (evening)
Enhanced protocol (10/3 blend) 300-500mcg total Once daily (evening)
Twice daily (advanced) 200-300mcg per dose Morning and evening
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Tesa/IPA Protocol
Injection site reactions (redness, itching)
Water retention (usually transient)
Tingling or numbness in extremities
Joint stiffness
Increased hunger (Ipamorelin effect)
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Active malignancy (GH may promote tumor growth)
Diabetic retinopathy
Pregnancy or breastfeeding
Pituitary disorders
Hypersensitivity to components
Research Evidence
BPC-157 Tesa/IPA Protocol
Status Extensively Studied Limited Research
References 6 studies 4 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.